Chronical diabetic complications from point of view of modern diabetology

Czech version

Authors: Milan Kvapil
Authors‘ workplace: Interní klinika 2. LF UK a FN Motol, Praha, Česká republika, přednosta prof. MUDr. Milan Kvapil, CSc., MBA
Published in: Forum Diab 2015; 4(2): 93-100
Category: Foreign Post

Overview

The basic purpose of the therapy is to prevent diabetes-specific late complications of hyperglycemia. Current diabetology is based on the results of randomized clinical trials. However, detailed analysis shows that the results are boundaries that define the general approach in the treatment of diabetes. For the treatment of the individual patient must be adapted therapy to as safe, effective simultaneously. Possibility of individual choice therapies are currently large, especially because there are new class of antidiabetic and hypolipidemic drugs. Apply basic principles – intensive care since the beginning of the disease, treatment with minimal risk of hypoglycemia, individual approach and education.

Key words:
diabetes mellitus – diabetic retinopathy – ezetimibe – heart failure – individual therapy – new antidiabetic drugs

Sources

1. Lind M, Svensson AM, Kosiborod M et al. Glycemic Control and Excess Mortality in Type 1 Diabetes. N Engl J Med 2014; 371(21): 1972–1982.

2. Guzder RN, Gatling W, Mullee MA et al. Early mortality from the time of diagnosis of Type 2 diabetes: a 5-year prospective cohort study with a local age – and sex-matched comparison cohort. Diabet Med 2007; 24(10): 1164–1167.

3. Nathan DM. DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014; 37(1): 9–16.

4. Gerstein HC, Miller ME, Genuth S et al. ACCORD Study Group. Long-term effects of intensive glukose lowering on cardiovascular outcomes. N Engl J Med 2011; 364(9): 818–828.

5. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995; 102(4):647–661.

6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–853.

7. Collins R, Armitage J, Parish S et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361(9374): 2005–2016.

8. IMPROVE IT. Dostupné z WWW: <http://www.cardiosource.org/science-and-quality/clinical-trials/i/improve-it.aspx?w_nav=RI>.

9. Blazing MA, Giugliano RP, Cannon CP et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J 2014; 168(2):205–212.e1. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2014.05.004>.

10. Abu El-Asrar AM, Al-Mezaine HS. Advances in the treatment of diabetic retinopathy. Saudi J Ophthalmol 2011; 25(2): 113–122.

11. Pazderová M. Současnost a perspektivy laserové léčby diabetické retinopatie. In: Kvapil M (ed). Diabetologie 2011. Triton: Praha 2011: 208–218. ISBN 978–80–7387–461–2.

12. Sosna M et al. Diabetický makulární edém. In Kvapil M (ed). Diabetologie 2013. Triton: Praha 2013: 235–250. ISBN 978–80–7387–656–2.

13. Molyneaux LM, Constantino MI, McGill M et al. Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract 1998; 42(2): 77–83.

14. Gerstein HC, Ambrosius WT, Danis R et al. ACCORD Study Group. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care 2013; 36(5): 1266–1271.

15. Lee SG, Kim JL, Lee HK et al. Simvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes. Graefes Arch Clin Exp Ophthalmol 2011; 249(3): 389–397.

16. IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103). Last updated November 2014. Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT00202878?term=Improve+IT&rank=1>.

17. Chew EY, Ambrosius WT, Davis MD et al. ACCORD Study Group. ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363(3): 233–244. Erratum in N Engl J Med 2011; 364(2): 190. N Engl J Med 2012; 367(25): 2458.

18. Fenofibrate. Product and Consumer Medicine Information. Dostupné z WWW: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=fenofibrate>.

19. Wilcox R, Kupfer S, Erdmann E. PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008; 155(4): 712–717. Erratum in: Am Heart J 2008; 156(2): 255.

20. Erdmann E, Dormandy JA, Charbonnel B et al. PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49(17): 1772–1780.

21. Wilcox R, Bousser MG, Betteridge DJ et al. PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38(3):865–873.

22. Dormandy JA, Charbonnel B, Eckland DJ et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279–1289.

23. Lester JW, Fernandes AW. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. Int J Clin Pract 2005; 59(2): 134–142.

24. Cushman WC, Evans GW, Byington RP et al. The ACCORD Study Group: Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 2010; 362(17):1575–1585. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1001286>.

25. Boden WE, O’Rourke RA, Teo KK et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356(15): 1503–1516. IMPROVE IT: Dostupné z DOI: <https://clinicaltrials.gov/>.

26. Informace dostupné z http: <http://cs.wikipedia.org/wiki/Hypot%C3%A9za>.

27. Informace dostupné z http: <http://cs.wikipedia.org/wiki/Princip>.

28. Kvapil M. Ezetimib – nová možnost pro kombinovanou léčbu hypercholesterolemie. Vnitr Lek 2004; 50(8): 643–644.

29. McPherson R, Hegele RA. Ezetimibe: rescued by randomization (clinical and mendelian). Arterioscler Thromb Vasc Biol 2015; 35(3): e13–15. Dostupné z DOI: <http://dx.doi.org/10.1161/ATVBAHA.114.30501>.

30. Stitziel NO, Won HH, Morrison AC et al. Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014; 371(22): 2072–2082.

31. Kvapil M, Pavlík T, Klika P et al. Základní analýza údajů o pacientech s diabetes mellitus. DMEV 2015; 18(Suppl 1): 21.

32. Scirica BM, Bhatt DL, Braunwald E et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317–1326.

33. White WB, Cannon CP, Heller SR et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1327–1335.

34. Green JB, Bethel MA, Paul SK et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013; 166(6): 983–989.e7. Dostupné z DOI: <http://dx,doi.org/10.1016/j.ahj.2013.09.003>.

35. Udell JA, Cavender MA, Bhatt D et al. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015; 3(5): 356–366. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(15)00044–3>.

36. Wallace E, Oates WE, Schwab RM. The Window Tax: A Case Study in Excess Burden. J Econ Perspect 2015; 29(1): 163–180. Dostupné z DOI: <http://dx.doi.org/10.1257/jep.29.1.163>.

37. Jena AB, Prasad V, Goldman DP et al. Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings. JAMA Intern Med 2015; 175(2): 237–244.

38. Salas M, Hughes D, Zuluaga A et al. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 2009; 12(6): 915–922.

39. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004; 27(9): 2149–2153.

40. Ho PM, Rumsfeld JS, Masoudi FA et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166(17): 1836–1841.

41. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120(8): 713–719.

42. Blonde L, San Juan ZT. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther 2012; 29(1): 1–13.

43. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008; 23(5): 611–614.

44. Melikian C, White TJ, Vanderplas A et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24(3): 460–467.

45. Rozenfeld Y, Hunt JS, Plauschinat C et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008; 14(2): 71–75.

46. Cheong C, Barner JC, Lawson KA et al. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther 2008; 30(10): 1893–1907.

47. Thayer S, Arondekar B, Harley C et al. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother 2010; 44(5): 791–799.

48. Blonde L, Wogen J, Kreilick C et al. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003; 5(6): 424–431.

49. Zvolský M. Činnost oboru diabetologie, péče o diabetiky v roce 2012. ÚZIS ČR. Aktuální informace 2013; 24. Dostupné z WWW: <http://www.uzis.cz/rychle-informace/cinnost-oboru-diabetologie-pece-diabetiky-roce-2012>.

Labels

Diabetology Endocrinology Internal medicine

Personalized medicine in diabetology in the context of consensual statement of the ADA/EASD 2015

Acute complications of diabetes mellitus from out-patient department perspective

Importance of self-monitoring of blood glucose

Compliance and individualized therapeutic targets in patients with DM2T treated with gliptins in monotherapy or in combination with other antidiabetic drugs: CITADELA Study

The most common gynecologic problems in diabetic women

Dermatologic manifestations of diabetes

Article was published in

Forum Diabetologicum

2015 Issue 2